{
    "nctId": "NCT00066378",
    "briefTitle": "Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer",
    "officialTitle": "An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 71,
    "primaryOutcomeMeasure": "Progression-free survival at 1 year",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Radiologically or clinically evident metastatic or locally recurrent disease\n  * Locally advanced disease in elderly patients\n  * Bone metastases only allowed\n* Failed prior tamoxifen therapy\n* No rapidly progressive visceral metastases\n* No uncontrolled CNS metastases\n* Hormone receptor status:\n\n  * Estrogen receptor and/or progesterone receptor positive\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Postmenopausal\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, defined by any of the following:\n\n  * Natural menopause with last menses more than 1 year ago\n  * Radiotherapy-induced oophorectomy with last menses more than 1 year ago\n  * Chemotherapy-induced menopause with last menses more than 1 year ago AND serum follicle-stimulating hormone and luteinizing hormone and plasma estradiol levels clearly in the postmenopausal range\n  * Surgical castration\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* Transaminases no greater than 2.5 times ULN\n* No unstable or uncompensated hepatic disease\n\nRenal\n\n* No unstable or uncompensated renal disease\n\nCardiovascular\n\n* No unstable or uncompensated cardiac disease\n\nPulmonary\n\n* No unstable or uncompensated pulmonary disease\n* No clinically active interstitial lung disease\n\n  * Asymptomatic chronic stable radiographic changes are allowed\n\nOther\n\n* No severe or uncontrolled systemic disease\n* No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix, nonmelanoma skin cancer, or contralateral breast cancer\n* No psychological, familial, sociological or geographical condition that would preclude study compliance and follow-up\n* No grade 2 or greater unresolved chronic toxicity from prior anticancer therapy\n* No unresolved ocular inflammation or infection\n* No known hypersensitivity to anastrozole or gefitinib or any of their excipients\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No prior trastuzumab (Herceptin)\n* No concurrent biologic therapy\n\nChemotherapy\n\n* No more than 1 line of prior chemotherapy in the adjuvant or metastatic setting\n* No concurrent chemotherapy\n\nEndocrine therapy\n\n* At least 2 years since prior aromatase inhibitors (e.g., anastrozole, letrozole, or exemestane) in the adjuvant setting\n* Prior tamoxifen or fulvestrant in the adjuvant and/or metastatic setting allowed\n* No prior aromatase inhibitors for metastatic disease\n* No other concurrent hormonal therapy\n\nRadiotherapy\n\n* No concurrent radiotherapy to any metastatic site\n\nSurgery\n\n* No surgery during and within 4 days after the last dose of gefitinib\n\nOther\n\n* At least 30 days since prior investigational drugs\n* No prior anti-epidermal growth factor therapy\n* No prior anti-vascular endothelial growth factor therapy (i.e., tyrosine kinase inhibitor receptor)\n* No concurrent administration of any of the following drugs:\n\n  * Phenytoin\n  * Carbamazepine\n  * Rifampin\n  * Phenobarbital\n  * Hypericum perforatum (St John's Wort)\n* No other concurrent investigational drugs or treatment\n* No other concurrent cancer treatment\n* No concurrent systemic retinoids\n* Concurrent bisphosphonate therapy for the treatment and prevention of bony metastases is allowed provided therapy was initiated prior to study entry\n\n  * Bisphosphonates may be initiated during study only for the treatment of hypercalcemia",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}